Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
New data shows that cabozantinib, a drug already approved in the treatment of clear cell renal cell carcinoma (ccRCC), elicited promising results in patients with less common non-clear…
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers…
A phase 1b study showed pembrolizumab and axitinib extended both overall survival (OS) and progression-free survival (PFS) in patients with previously untreated mRCC. “The risk of death was…
With the growth of immunotherapies in recent years as an effective melanoma treatment option, there are still patients who do not respond well to immunotherapies. Hildur Helgadottir, MD,…
Interim results from the preliminary analysis of the JAVELIN-Renal 101 trial suggest that adding immunotherapy to a targeted agent appears to significantly improve progression-free survival (PFS) when compared with a…
A team of engineers are hoping the 12-sided cage they developed will one day help fight cancer. Made from self-assembling silica, the nanocage is only 11 nanometers across—for…
According to patient recorded outcomes, the IN-Motion151 study met its co-primary endpoint of progression-free survival (PFS). Lead author Bernard Escudier, MD, of the Institut Gustave Roussy in Villejuif, France,…
